Liver Cancer Trial, Recruiting NCT03253536 Sponsor: Ludwig-Maximilians - University of Munich Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT03253536
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with liver cancer (hepatocellular carcinoma), either confirmed by a tissue sample or by medical imaging
  • People who have 1 to 3 liver tumours that are suitable for a type of targeted radiation treatment called stereotactic body radiation therapy (SBRT)
  • People whose case has been reviewed by a team of specialists who have recommended this radiation treatment
  • People aged 18 or older
  • People who are willing and able to sign a consent form agreeing to take part in the study
  • People who have enough mental and verbal ability to fill out standardised questionnaires, as assessed by the study doctor

Who may not be able to join:

  • People under 18 years of age
  • People who have previously received systemic (whole-body) drug treatments specifically for liver cancer
  • People who are currently receiving any systemic cancer treatment at the same time
  • People whose cancer has spread to other parts of the body (distant metastases)
  • People who may not be able to follow the study requirements or complete the required questionnaires
  • People who are unable to receive a contrast-enhanced CT scan (a type of detailed X-ray that uses a special dye) for treatment planning
  • People who are not able to give informed consent to participate
  • People who are under legal guardianship or custody arrangements that would prevent independent consent

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Falk Roeder, MD, Department of Radiation Oncology, University Hospital, LMU Munich

Phone: +49 89 4400 73729

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Ludwig-Maximilians - University of Munich
Registry
ClinicalTrials.gov
Start date
10 July 2017
Est. completion
10 July 2022

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Quality of life

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov